Advancing the field of drug delivery: Taking aim at cancer

Cancer Cell

Volumn 4, Issue 5, 2003, Pages 337-341

  Moses, Marsha A ^a   Brem, Henry ^b   Langer, Robert ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; CARMUSTINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FENTANYL; GOSERELIN; LIPOSOME; LYPRON DEPOT; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NICOTINE; PEGINTERFERON ALPHA2B; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIPTORELIN; UNCLASSIFIED DRUG; ZINOSTATIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BRAIN CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CARCINOMATOUS MENINGITIS; CARDIOTOXICITY; CHEMOPROPHYLAXIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG USE; GLIOBLASTOMA; HUMAN; KAPOSI SARCOMA; LIVER CELL CARCINOMA; MICROENCAPSULATION; MYCOSIS; NANOTECHNOLOGY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT;

EID: 0344494508     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00276-9     Document Type: Review

References (35)

1. st Century:1997;Princeton University Press, Princeton, New Jersey. pp. 240.
2. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., Black K., Sisti M., Brem S., Mohr G., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 345:1995;1008-1012.
3. Brem H., Langer R. Polymer-based drug delivery to the brain. Sci. Med. 3:1996;2-11.
4. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
5. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., Torchilin V.P., Munn L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62:2002;6831-6836.
6. Dijkmana G.A., del Moral P.F., Plasman J.W., Kums J.J., Delaere K.P., Debruyne F.M., Hutchinson F.J., Furr B.J. A new extra long acting depot preparation of the LHRH analogue Zoladex®. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer. J Steroid Biochem. Mol. Biol. 37:1990;933-936.
7. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2:2003;347-360.
8. Ewend M.G., Sampath P., Williams J.A., Tyler B.M., Brem H. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast cancer. Neurosurgery. 43:1998;1185-1193.
9. Fernandez C.A., Butterfield C., Jackson G., Moses M.A. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of TIMP-2. Loop 6 is a novel inhibitor of angiogenesis J. Biol. Chem. 278:2003;40989-40995.
10. Henningfield J.E. Drug therapy-Nicotine medications for smoking cessation. N. Engl. J. Med. 333:1995;1196-1203.
11. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1:1999;241-263.
12. Jain R.K. Normalizing the tumor vasculature with anti-angiogenic therapy. A new paradigm for combination therapy Nat. Med. 7:2001;987-989.
13. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., Flynn E., Fogler W.E., Sim B.K., Allred E.N., Pirie-Shepherd S.R., Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61:2001;7669-7674.
14. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;15-24.
15. Langer R. Drug delivery and targeting. Nature. 392(Suppl):1998;5-10.
16. Langer R., Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 263:1976;797-800.
17. Langer R., Brem H., Falterman K., Klein M., Folkman J. Isolation of a cartilage factor that inhibits tumor neovascularization. Science. 1193:1976;70-72.
18. Laws E.R., Morris A.M., Maartens N. Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery. 53:2003;255-269.
19. Man S., Bocci G., Francia G., Green S.K., Jothy S., Hanahan D., Bohlen P., Hicklin D.J., Bergers G., Kerbel R.S. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62:2002;2731-2735.
20. McCarthy, S. (2003). Antiangiogenesis drug promising for metastatic colorectal cancer - New treatments for colorectal cancer might improve patients' survival, investigators reported at ASCO. Lancet 361, 1959.
21. Moses M.A., Langer R. Inhibitors of angiogenesis. Biotechnology. 9:1991;630-634.
22. Moses M.A., Wiederschain D., Wu I., Fernandez C.A., Ghazizadeh V., Lane W.S., Flynn E., Sytkowski A., Tao T., Langer R. Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. USA. 96:1999;2645-2650.
23. Ogawa Y., Yamamoto M., Okada H., Yashiki T., Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid and copoly(lactic/glycolic acid). Chem. Pharm. Bull. 36:1988;1095-1103.
24. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev. 28:1997;43-70.
25. Okada H., Yamazaki I., Ogawa Y., Hirai S., Yashiki T., Mima H. Vaginal absorption of a potent luteinizing-hormone-releasing hormone analog (leuprolide) in rats-1-absorption by various routes and absorption enhancement. J. Pharm. Sci. 71:1982;1367-1371.
26. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M.A., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma Cell. 79:1994;315-328.
27. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth Cell. 88:1997;277-285.
28. Peppas N., Langer R. New challenges in biomaterials. Science. 263:1994;1715-1720.
29. Prausnitz, M., Mitragotri, S., and Langer, R. (2003). Current status and future potential of transdermal drug delivery. Nature Drug Discovery, in press.
30. Richards-Grayson A., Choi I., Tyler B., Wang P., Brem H., Cima M., Langer R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. 2:2003;709-710.
31. Santini J., Cima M., Langer R. A controlled-release microchip. Nature. 397:1999;335-338.
32. Sartor O., Dineen M.K., Perez-Marreno R., Chu F.M., Carron G.J., Tyler R.C. An eight-month clinical study of LA-2575 30.0 mg. A new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer Urology. 62:2003;319-323.
33. Valtonen S., Timonen U., Toivanen P., Kalimo H., Kivipelto L., Heiskanen O., Unsgaard G., Kuurne T. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas. a randomized double-blind study Neurosurgery. 41:1997;44-49.
34. Weingarten J.D., Sipos E.P., Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J. Neurosurg. 82:1995;635-640.
35. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., Whittle I.R., Jaaskelainen J., Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomas. Neuro-oncol. 5:2003;79-88.